secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2021-09-02T23:59:59+00:00
Accession:  0001564590-21-046992
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics appoints Jeff Knight as COO with $400k salary, 40% bonus, and 160k-share option grant
--------------------------------------------------------------------------------

- Appointment effective August 30, 2021; Knight most recently SVP at Poseida Therapeutics.
- Annual base salary of $400,000 with target annual incentive bonus of 40% of base.
- Received option to purchase 160,000 shares vesting 25% on Aug 30, 2022 then monthly over 3 years.
- Sign-on bonus of $40,000 in connection with commencement of employment.
- Knight brings over 25 years of clinical drug development experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000156459021046992/0001564590-21-046992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000156459021046992/crnx-8k_20210830.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-046992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer